A 11-year old female patient with severe thalassemia,receipt a lentivirus-based cell and gene therapy(CGT)therapy in Shenzhen Children's Hosptial on July 27th,2021.At the two follow-up visits after discharge,patient were continuously tested positive for HIV screening through HIV Ag/Ab Combo assay(chemiluminescence Immunoassay),and the viral load results of HIV-1 nucleic acid testing(NAT)were both＞5 000 copies/ml.The patient can be diagnosed with HIV infection according to the National Guideline for Detection of HIV/AIDS(2020 Revised Edition).The thorough investigation findings and supplementary experiment results indicated that the false-positive HIV-1 NAT results was caused by cross-reactivity between the target sites detected by conventional HIV-1 NAT reagents and the lentiviral vectors fragments integrated into the genome of patient's hematopoietic stem/progenitor cells.In conclusion,it is important for laboratories to select appropriate HIV-1 NAT testing platforms which won't cause cross-reactivity for the testing of samples from patients who have been treated with HIV-derived vectors.It is also recommended to design and develop NAT testing platforms with multiple target regions labeled by different fluorescents for HIV NAT supplementation experiment to reduce the risk of false-positive diagnoses of HIV infection.
维普
万方数据
